An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase

Trial Profile

An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ODYSSEY KIDS
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Jan 2018 Status changed from active, no longer recruiting to recruiting.
    • 17 Jan 2018 Planned number of patients changed from 30 to 40.
    • 17 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top